Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Neoplasm Metastasis

Carcinoma

Carcinoma, Squamous Cell

Squamous Cell Carcinoma of Head and Neck

Lung Neoplasms

Small Cell Lung Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Triple Negative Breast Neoplasms

Cholangiocarcinoma

Uterine Cervical Neoplasms

Hematologic Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

Adenocarcinoma

Head and Neck Neoplasms

Hematologic Diseases

Neoplastic Processes

Small Cell Lung Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Bile Duct Cancer

Antineoplastic Agents

All Drugs and Chemicals

Margetuximab

tebotelimab 1 mg

tebotelimab 3 mg

tebotelimab 10 mg

tebotelimab 30 mg

tebotelimab 120 mg

tebotelimab 300 mg

tebotelimab 400 mg

tebotelimab 600 mg

tebotelimab 800 mg

tebotelimab 1200 mg

margetuximab

Ashley Ward, MD

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Safety

Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.

ORR is the percentage of participants who have a complete response or a partial response to treatment.

DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first. Median DoR is the time when 50% of responders are still in response.

PFS is defined as the time from the first dose date to the date of first documented PD or death from any cause, whichever occurs first. Median PFS is the time when 50% of participants remain free of PD or death.

OS is defined as the time from the first dose date to the date of death from any cause. Median OS is the time when 50% of participants are still alive.

MacroGenics

Spots Global Cancer Trial Database for tebotelimab 30 mg